Picture [iito] No Tracking 650x80px
Document › Details

Protagen AG. (12/20/16). "Press Release: Protagen AG Successfully Joined Forces with Novartis to Support Clinical Development of a Novel Compound in an Autoimmune Indication".

Organisations Organisation Protagen AG
  Today Oncimmune Germany GmbH
  Organisation 2 Novartis Pharma AG
  Group Novartis (Group)
Products Product SeroTag® Autoantibody Profiling
  Product 2 clinical research
Persons Person Lautscham, Georg (Protagen 201610– CEO before CBO)
  Person 2 Russell, Clare (formerly Jones) (BioStrata 201404– Managing Director before Chempetitive UK + Alto Marketing)

PROTAGEN AG, a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced the successful completion a collaboration agreement with Novartis Pharma AG. During the collaboration, Protagen utilized its proprietary SeroTag technology to discover prediction as well as patient stratification markers for a novel drug being developed by Novartis.

Protagen CBO Georg Lautscham commented: “Our innovative SeroTag technology has proven on numerous occasions that it can monitor the immune-health status of patients, thereby allowing for the first time the systematic determination of response prediction and disease as well as patient stratification markers to select the most appropriate drug and therapy in autoimmune indications. This was evaluated in our collaboration with Novartis and we would like to thank Novartis’ R&D team for the excellent, productive and collaborative relationship.”

About Protagen - Diagnostics Differentiated

Headquartered in Dortmund Germany, Protagen specializes in Pharma development services and novel companion diagnostics, in the field of immuno-oncology and autoimmune disease.

Protagen uses its proprietary SeroTag biomarker discovery platform to identify valuable biomarkers that support Pharma development and its NavigAID products to personalize treatment with targeted therapies. With state-of-the-art bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen is expanding its own pipeline of critically informative biomarkers and collaborates with other organizations to commercialize valuable tools for better personalized treatment strategies for cancer and autoimmune disease patients.

Dr. Georg Lautscham
T +49 231 9742 6300

Media Enquiries
Dr. Clare Russell
Managing Director
T +44 1223 253787
M +44 7812 343412

Record changed: 2017-02-03


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Oncimmune (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top